{"id":"NCT05323734","sponsor":"Marinus Pharmaceuticals","briefTitle":"Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy","officialTitle":"A Phase 3, Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Complex (TSC)-Related Epilepsy (TrustTSC)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-04-01","primaryCompletion":"2024-09-09","completion":"2024-10-14","firstPosted":"2022-04-12","resultsPosted":"2025-07-11","lastUpdate":"2025-07-11"},"enrollment":129,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Tuberous Sclerosis Complex"],"interventions":[{"type":"DRUG","name":"Ganaxolone","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Ganaxolone (GNX)","type":"EXPERIMENTAL"},{"label":"Placebo matching GNX","type":"PLACEBO_COMPARATOR"}],"summary":"This is a Phase 3, global, double-blind, randomized, placebo-controlled study of adjunctive GNX treatment in children and adults with TSC-related epilepsy. The study consists of a 4-week prospective Baseline phase, defined as the first 28 days following screening, followed by a double-blind phase consisting of a 4-week titration period (Day 1 to Day 28) and a 12-week maintenance period (Day 29 to Week 16).","primaryOutcome":{"measure":"Percent Change From Baseline in 28-day Seizure Frequency for Primary Seizure Type During Double Blind Period","timeFrame":"Baseline (Day 1), Day 28","effectByArm":[{"arm":"Ganaxolone","deltaMin":-7.5,"sd":60.43},{"arm":"Matching Placebo","deltaMin":13.57,"sd":77.374}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0904"}]},"eligibility":{"minAge":"1 Year","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":63,"countries":["United States","Australia","Canada","China","France","Germany","Israel","Italy","Spain","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":64},"commonTop":["Somnolence","Pyrexia","Seizure","Fatigue","Decreased Appetite"]}}